AbbVie seeks lift from 'guided missile' cancer drug with $10 billion ImmunoGen deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Immunogen (IMGN) shares surge on news of takeover by AbbVie (ABBV)
November 30, 2023 9:09 AM ESTAbbVie (NYSE: ABBV) announced Thursday that it will acquire Immunogen (NASDAQ: IMGN) and its flagship cancer therapy, Elahere, in a deal worth $31.26 per share.
The transaction values ImmunoGen at a total equity value of approximately $10.1 billion and is expected to close in the middle of 2024.
Elahere... More
